Therefore, LKB1 may require secondary mutations, such as PTEN or alterations in JNK1/2 signaling to direct the progression of the de novo tumors to SCC vs. ASC or to promote the progression of ASC to SCC. The gene discussed is STK11; the disease is Tako-tsubo cardiomyopathy.